Rouvax™

GlaxoSmithKline · Phase 2 active Biologic

At a glance

Generic name	Rouvax™
Also known as	Measles, measles vaccine
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rouvax™ CI brief — competitive landscape report
Rouvax™ updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI